Advanced search
Publication Cover
Postgraduate Medicine Volume 126, 2014 - Issue 7
Submit an article Journal homepage
326
Views
25
CrossRef citations to date
0
Altmetric
Clinical Features

Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist

Malcolm A. Young Senior Director, Clinical Pharmacology, Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NCCorrespondence[email protected]
, PhD,
Jeffrey A. Wald Senior Director, Clinical Pharmacology, Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NC
, PhD,
Jessica E. Matthews Medical Affairs Scientific Director, GlaxoSmithKline, Research Triangle Park, NC
, BS,
Rhona Scott Director, Clinical Development, GlaxoSmithKline, Stockley Park, UK
, BSc (Hons),
Rebecca J. Hodge Director, Discovery Medicine, GlaxoSmithKline, Research Triangle Park, NC
, DMV,
Hui Zhi Manager, Clinical Statistics, GlaxoSmithKline, Research Triangle Park, NC
, PhD &
Rickey R. Reinhardt Head of Clinical Development, GlaxoSmithKline, Upper Merion, PA
, MD, PhD show all
Pages 84-97 | Published online: 13 Mar 2015

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Marc S. Rendell. (2018) Albiglutide for the management of type 2 diabetes. Expert Review of Endocrinology & Metabolism 13:1, pages 1-8.
Read now
Marc S. Rendell. (2017) The safety of albiglutide for the treatment of type 2 diabetes. Expert Opinion on Drug Safety 16:9, pages 1089-1097.
Read now
Marc S. Rendell. (2016) Albiglutide: a unique GLP-1 receptor agonist. Expert Opinion on Biological Therapy 16:12, pages 1557-1569.
Read now
Jessica E. Matthews, Rickey R. Reinhardt & Molly C. Carr. (2016) Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes. Postgraduate Medicine 128:4, pages 391-397.
Read now

Articles from other publishers (21)

Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang & Jincheng Wang. (2023) Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition. Acta Pharmaceutica Sinica B 13:6, pages 2383-2402.
Crossref
Shurui Hong. (2023) Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes. BIO Web of Conferences 61, pages 01006.
Crossref
Fatemeh Mirzaei, Iraj Khodadadi, Nesrine Majdoub, Seyyed Alireza Vafaei, Heidar Tayebinia & Ebrahim Abbasi. (2022) Role of Glucagon-like Peptide-1 (GLP-1) Agonists in the Management of Diabetic Patients with or without COVID-19. The Open Medicinal Chemistry Journal 16:1.
Crossref
Federica Ferrari, Antonio Moretti & Roberto Federico Villa. (2022) Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics 239, pages 108277.
Crossref
S. M. Shatil Shahriar, Jeong Man An, Mohammad Nazmul Hasan, Sachin S. Surwase, Yeu-Chun Kim, Dong Yun Lee, Sungpil Cho & Yong-kyu Lee. (2021) Plasmid DNA Nanoparticles for Nonviral Oral Gene Therapy. Nano Letters 21:11, pages 4666-4675.
Crossref
Noura G. Eissa, Mahmoud Elsabahy & Ayat Allam. (2021) Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs. International Journal of Pharmaceutics 597, pages 120317.
Crossref
Federica Ferrari, Antonio Moretti & Roberto Federico Villa. (2020) The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs. Pharmacological Research 160, pages 105018.
Crossref
Bonnie C. Shaddinger, Georgios Vlasakakis, Joseph Soffer, Karl M. Thorpe, Daniel Hatch & Antonio J. Nino. (2018) A Randomized, Double‐Blind, Single‐Dose, Crossover Study to Demonstrate the Bioequivalence of 2 Formulations of Albiglutide in Healthy Adult Participants. Clinical Pharmacology in Drug Development 8:3, pages 361-370.
Crossref
Dilip Sharma, Suril Verma, Shivani Vaidya, Kiran Kalia & Vinod Tiwari. (2018) Recent updates on GLP-1 agonists: Current advancements & challenges. Biomedicine & Pharmacotherapy 108, pages 952-962.
Crossref
Kyle W. Sloop, Daniel A. Briere, Paul J. Emmerson & Francis S. Willard. (2018) Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases?. ACS Pharmacology & Translational Science 1:1, pages 3-11.
Crossref
Minzhi Yu, Mason M. Benjamin, Santhanakrishnan Srinivasan, Emily E. Morin, Ekaterina I. Shishatskaya, Steven P. Schwendeman & Anna Schwendeman. (2018) Battle of GLP-1 delivery technologies. Advanced Drug Delivery Reviews 130, pages 113-130.
Crossref
Sten Madsbad & Jens J. Holst. 2018. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment 571 615 .
Sten Madsbad & Jens J. Holst. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment 1 45 .
Bonnie C. Shaddinger, Malcolm A. Young, Julia Billiard, David A. Collins, Azra Hussaini & Antonio Nino. (2017) Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study. The Journal of Clinical Pharmacology 57:10, pages 1322-1329.
Crossref
Philip D. Home, Bo Ahrén, Jane E.B. Reusch, Marc Rendell, Peter N. Weissman, Deborah T. Cirkel, Diane Miller, Philip Ambery, Molly C. Carr & Michael A. Nauck. (2017) Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice 131, pages 49-60.
Crossref
Kelli M. Luginbuhl, Jeffrey L. Schaal, Bret Umstead, Eric M. Mastria, Xinghai Li, Samagya Banskota, Susan Arnold, Mark Feinglos, David D’Alessio & Ashutosh Chilkoti. (2017) One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer. Nature Biomedical Engineering 1:6.
Crossref
Bo Ahrén, Molly C. Carr, Karen Murphy, Christopher Perkins, Marc Rendell, Jason Mallory, Timothy Wilson & Susan Johnson. (2017) Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. Diabetes Research and Clinical Practice 126, pages 230-239.
Crossref
L. OtvosJr.Jr.. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III 131 156 .
Sten Madsbad. (2016) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes, Obesity and Metabolism 18:4, pages 317-332.
Crossref
Oscar Duems-Noriega & Sergio Ariño-Blasco. (2015) Subcutaneous fluid and drug delivery: safe, efficient and inexpensive. Reviews in Clinical Gerontology 25:2, pages 117-146.
Crossref
Hannah A. Blair & Gillian M. Keating. (2015) Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75:6, pages 651-663.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.